Real-Life Evidence on Stroke Prevention in SPAF

• Status: Completed
• Trial end date: 2015-09-01

Summary

To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting

Details

• Lead Sponsor: Bayer
• Collaborator: Janssen, LP
• Treatments: Rivaroxaban; Vitamin K; Vitamins